A Tale of Hope and Caution: Update on Gram-negative and Clostridium difficile Infections

Activity Post Test and Evaluation Form

Post Test

Please note that to receive credit you must achieve a score of at least 70%.

Physicians: Certificate of Credit will be emailed within 4 weeks of successful completion of the activity.

Pharmacists: The information that you participated will be uploaded to CPE Monitor and you will be able to access your credits from the profile you set up with NABP. For more information, please visit http://www.nabp.net/.

Question Title

* 1. Which of the following bacteria has been identified by the World Health Organization as a critical priority pathogen?

Methicillin-resistant S. aureus

Carbapenem-resistant P. aeruginosa

Fluoroquinolone-resistant S. pneumoniae

Vancomycin-resistant C. difficile

Question Title

* 2. An appropriate antimicrobial choice for the treatment of an infection caused by an ESBL-producing organism can include any of the following except:

Ceftriaxone

Ceftazidime-avibactam

Meropenem

Imipenem

Question Title

* 3. Newer beta-lactamase inhibitors (e.g., avibactam, vaborbactam) are effective against all of the following beta-lactamases except:

Class A ESBLs

Class A carbapenemases (e.g., KPCs)

Class B metallo-beta-lactamases

Class A narrow-spectrum beta-lactamases

Question Title

* 4. For a patient experiencing a recurrent CDI episode, which of the following regimens will likely result in the lowest risk of a subsequent episode?

Metronidazole alone

Vancomycin alone

Bezlotoxumab alone

Vancomycin plus bezlotoxumab

Question Title

* 5. According to the latest IDSA/SHEA C. difficile guidelines, which of the following would be appropriate treatment of an initial non-severe episode of CDI?

Vancomycin

Fidaxomicin

Rifaximin

Either vancomycin or fidaxomicin

Question Title

* 6. According to the latest IDSA/SHEA C. difficile guidelines, which of the following would be an appropriate choice for a first recurrence of CDI if vancomycin was used for the initial CDI episode?

Metronidazole

Vancomycin plus metronidazole

Fidaxomicin

Fecal microbiota transplantation